B族维生素在慢性肾脏病治疗中的研究进展

doi:10.3969/j.issn.1004-583X.2026.04.013

摘要/Abstract

摘要：

B族维生素缺乏在慢性肾脏病(chronic kidney disease,CKD)患者中非常普遍,其导致的高同型半胱氨酸血症是CKD进展和心血管风险增加的重要促进因素,可形成疾病恶化的病理循环。临床干预中,合理补充叶酸、维生素B₆、维生素B₁₂等B族维生素,是控制同型半胱氨酸水平、改善预后的重要策略,而特殊环境与患者共病等个体因素,则使管理更复杂,对治疗提出了个体化的要求。本文将系统阐述B族维生素在CKD中的关键作用,并分析其与同型半胱氨酸的机制关联,同时,就当前临床研究中的结论差异、环境与共病对治疗的影响,以及新治疗技术的潜力和挑战进行探讨,为CKD的个体化与精准化营养管理提供理论参考。

关键词: 肾病, B族维生素, 同型半胱氨酸, 精准医学, 高原

中图分类号:

R692

王家璇, 马玉琴, 梁金秋, 曾浩然, 肖梦云. B族维生素在慢性肾脏病治疗中的研究进展[J]. 临床荟萃, 2026, 41(4): 369-373.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.04.013

https://www.lchc.cn/CN/Y2026/V41/I4/369

参考文献 43

[1]	Chen W, Feng J, Ji P, et al. Association of hyperhomocysteinemia and chronic kidney disease in the general population: A systematic review and meta-analysis[J]. BMC Nephrol, 2023, 24(1): 247. doi:10.1186/s12882-023-03295-y.
[2]	Chen T, Li Y, Wang J, et al. Correlation among cystatin C, homocysteine and arteriosclerosis indexes in patients with chronic kidney disease[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2021, 46(12): 1338-1345. doi:10.11817/j.issn.1672-7347.2021.210059.
[3]	Azzini E, Ruggeri S, Polito A. Homocysteine: Its possible emerging role in at-risk population groups[J]. Int J Mol Sci, 2020, 21(4): 1421. doi:10.3390/ijms21041421.
[4]	Wang L, Li X, Montazeri A, et al. Phenome-wide association study of genetically predicted B vitamins and homocysteine biomarkers with multiple health and disease outcomes: Analysis of the UK Biobank[J]. Am J Clin Nutr, 2023, 117(3): 564-575. doi:10.1016/j.ajcnut.2023.01.005. pmid: 36811473
[5]	Angelini A, Cappuccilli ML, Magnoni G, et al. The link between homocysteine, folic acid and vitamin B12 in chronic kidney disease[J]. G Ital Nefrol, 2021, 38(4): 2021-vol4.
[6]	赵艳颖, 王素青, 王晓阳, 等. 维生素B12并烟酸缺乏症1例并文献复习[J]. 临床荟萃, 2015, 30(8):931-934.
[7]	李佳宁, 刘思颖, 姜福丽, 等. 维生素B1与糖尿病微血管并发症[J]. 临床荟萃, 2012, 27(22):2013-2017.
[8]	Oudman E, Wijnia JW, Severs D, et al. Wernicke’s encephalopathy in acute and chronic kidney disease: A systematic review[J]. J Ren Nutr, 2024, 34(2): 105-114. doi:10.1053/j.jrn.2023.10.003.
[9]	Yang C, Wijerathne CUB, Tu GW, et al. Ischemia-reperfusion injury reduces kidney folate transporter expression and plasma folate levels[J]. Front Immunol, 2021, 12: 678914. doi:10.3389/fimmu.2021.678914.
[10]	Garibotto G, Picciotto D, Verzola D, et al. Homocysteine exchange across skeletal muscle in patients with chronic kidney disease[J]. Physiol Rep, 2023, 11(6): e15573. doi:10.14814/phy2.15573.
[11]	Chen W, Liang X, Liang G, et al. Hyperhomocysteinemia and its association with decreased glomerular filtration rate in patients with chronic kidney disease: A comprehensive meta-analysis[J]. PeerJ, 2025, 13: e20064. doi:10.7717/peerj.20064.
[12]	Yaqub N, Zubairi AM, Kanani F, et al. An insight to hyperhomocysteinaemia in CKD patients of a tertiary care hospital, karachi[J]. J Coll Physicians Surg Pak, 2025, 35(2): 180-184. doi:10.29271/jcpsp.2025.02.180. pmid: 39936195
[13]	Xiong Y, Zhang Y, Zhang F, et al. Genetic evidence supporting the causal role of homocysteine in chronic kidney disease: A mendelian randomization study[J]. Front Nutr, 2022, 9: 843534. doi:10.3389/fnut.2022.843534.
[14]	Wu J, Liu D, Yang L, et al. Association between serum homocysteine levels and severity of diabetic kidney disease in 489 patients with type 2 diabetes mellitus: A single-center study[J]. Med Sci Monit, 2022, 28: e936323.
[15]	Xie L, Ma S, Ding N, et al. Homocysteine induces podocyte apoptosis by regulating miR-1929-5p expression through c-Myc, DNMT1 and EZH2[J]. Mol Oncol, 2021, 15(11): 3203-3221. doi:10.1002/1878-0261.13032. pmid: 34057794
[16]	Lei Y, Liu R, Zhao Y. Serum homocysteine and left ventricular hypertrophy in adults with chronic kidney disease: A case-control study[J]. Medicine (Baltimore), 2024, 103(47): e40577. doi:10.1097/md.0000000000040577.
[17]	Wu HHL, McDonnell T, Chinnadurai R. Physiological associations between vitamin B deficiency and diabetic kidney disease[J]. Biomedicines, 2023, 11(4):1153. doi: 10.3390/biomedicines11041153.
[18]	Capelli I, Cianciolo G, Gasperoni L, et al. Folic acid and vitamin B12 administration in CKD, why not?[J]. Nutrients, 2019, 11(2): 383. doi:10.3390/nu11020383.
[19]	Prasad K. Atherogenic effect of homocysteine, a biomarker of inflammation and its treatment[J]. Int J Angiol, 2024, 33(4): 262-270. doi:10.1055/s-0044-1788280.
[20]	Maideen NMP. Adverse effects associated with long-term use of proton pump inhibitors[J]. Chonnam Med J, 2023, 59(2): 115-127. doi:10.4068/cmj.2023.59.2.115. pmid: 37303818
[21]	Matsumoto AK, Michelin AP, Semeão LO, et al. A randomized trial of short-term treatment with folic acid to reduce the oxidative stress of patients with chronic kidney disease[J]. Curr Drug Metab, 2021, 22(14): 1139-1150. doi:10.2174/1389200222666211210153145. pmid: 34895119
[22]	Chan CW, Lin BF. Folate deficiency enhanced inflammation and exacerbated renal fibrosis in high-fat high-fructose diet-fed mice[J]. Nutrients, 2023, 15(16):3616. doi: 10.3390/nu15163616.
[23]	Hasson DC, Surapaneni A, Rebholz CM, et al. Association of dietary micronutrient intake and the metabolome in children with CKD[J]. Clin J Am Soc Nephrol, 2025, 20(11): 1536-1548. doi:10.2215/CJN.0000000811.
[24]	Heybeli C, Kazancioglu R, Smith L, et al. Risk factors for high fall risk in elderly patients with chronic kidney disease[J]. Int Urol Nephrol, 2022, 54(2): 349-356. doi:10.1007/s11255-021-02884-w.
[25]	张佳楠, 孙琳琳, 詹潇燕, 等. 血清维生素B₁₂与老年2型糖尿病轻度认知功能障碍的关系[J]. 临床荟萃, 2024, 39(1):34-37. doi: 10.3969/j.issn.1004-583X.2024.01.005
[26]	Ledda C, Cannizzaro E, Lovreglio P, et al. Exposure to toxic heavy metals can influence homocysteine metabolism?[J]. Antioxidants (Basel), 2019, 9(1):30. doi:10.3390/antiox9010030.
[27]	Ashfaq F, Aljaadi AM, Salaka AS, et al. Comparison of TCN-2 (776C>G) gene polymorphism and vitamin B12 status with different body mass index among Saudi adults[J]. Life (Basel), 2023, 13(5):1185.doi:10.3390/life13051185.
[28]	Wang SY, Gao J, Zhao JH. Effects of high altitude on renal physiology and kidney diseases[J]. Front Physiol, 2022, 13: 969456. doi:10.3389/fphys.2022.969456.
[29]	Zhang L, Feng E, Baima S, et al. High altitude renal syndrome: Four elements or one source?[J]. Ren Fail, 2025, 47(1): 2482125. doi:10.1080/0886022X.2025.2482125.
[30]	Fitria L, Prihartono NA, Ramdhan DH, et al. Environmental and occupational risk factors associated with chronic kidney disease of unknown etiology in west javanese rice farmers, indonesia[J]. Int J Environ Res Public Health, 2020, 17(12): 4521. doi:10.3390/ijerph17124521.
[31]	Curran CS, Kopp JB. The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease[J]. J Transl Med, 2023, 21(1): 706. doi:10.1186/s12967-023-04584-8.
[32]	Juszczak AB, Kupczak M, Konecki T. Does vitamin supplementation play a role in chronic kidney disease?[J]. Nutrients, 2023, 15(13): 2847. doi:10.3390/nu15132847.
[33]	Galal ARM, Teama NM, Abu-Elfotuha K, et al. The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: Randomized controlled trial[J]. BMC Nephrol, 2025, 26(1): 468. doi:10.1186/s12882-025-04399-3.
[34]	Sengupta P, Biswas S, Roy T. Comparative study to evaluate the effect of low-protein diet supplementation with taurine and n-acetylcysteine, n-acetylcysteine and pyridoxamine dihydrochloride in preventing the progression of chronic renal failure in patients with non-diabetic kidney disease[J]. J Assoc Physicians India, 2022, 70(5): 11-12. pmid: 35598122
[35]	Hu C, Tang T. Association between niacin intake and chronic kidney disease in male participants-a cross-sectional study from the NHANES (2005-2018)[J]. Front Nutr, 2025, 12: 1578118. doi:10.3389/fnut.2025.1578118.
[36]	Xiang M, Peng J, Gui Z, et al. Association of dietary niacin intake with all-cause mortality in chronic kidney disease: A retrospective cohort study of NHANES[J]. PloS One, 2025, 20(2): e0313398. doi:10.1371/journal.pone.0313398.
[37]	Zhou Z, Yao X. Dietary niacin intake and mortality among chronic kidney disease patients[J]. Front Nutr, 2024, 11: 1435297. doi:10.3389/fnut.2024.1435297.
[38]	Zhang D, Wu H, Gong S, et al. The generalized association between niacin intake and cardiovascular events in US adults living with chronic kidney disease[J]. Int J Vitam Nutr Res, 2025, 95(4): 37256. doi:10.31083/IJVNR37256.
[39]	Savic-Hartwig M, Kerlikowsky F, van de Flierdt E, et al. A micronutrient supplement modulates homocysteine levels regardless of vitamin B biostatus in elderly subjects[J]. Int J Vitam Nutr Res, 2024, 94(2): 120-132. doi:10.1024/0300-9831/a000777.
[40]	Chan CKW, Szeto CC, Lee LKC, et al. A sub-10-nm, folic acid-conjugated gold nanoparticle as self-therapeutic treatment of tubulointerstitial fibrosis[J]. Proc Natl Acad Sci U S A, 2023, 120(42): e2305662120. doi:10.1073/pnas.2305662120.
[41]	Yan LJ, Zhang FR, Zeng YR, et al. Serum folate and all-cause mortality is of non-linear relationship among population with chronic kidney disease: A retrospective cohort study[J]. Int J Gen Med, 2021, 14: 2695-2702. doi:10.2147/IJGM.S314904.
[42]	Liu M, Ye Z, Yang S, et al. Relationship of dietary intake of food folate and synthetic folic acid intake from fortified foods with all-cause mortality in individuals with chronic kidney disease[J]. Food Funct, 2024, 15(2): 559-568. doi:10.1039/d3fo03927g. pmid: 38164661
[43]	Takahashi R, Bui TA, Elali I, et al. The association of niacin use with kidney outcomes and mortality[J]. Am J Nephrol, 2025, 56(4): 457-467. doi:10.1159/000543098.

B族维生素在慢性肾脏病治疗中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姜少利, 闫国胜, 李丽丽. 终末期维持性血液透析患者营养不良-炎症复合综合征发生情况及其危险因素[J]. 临床荟萃, 2026, 41(4): 312-317.
[2]	宋晨璐, 亓晓菁, 陈怿鹏, 邢广群. 不健康生活方式及吸烟与原发性膜性肾病的关系[J]. 临床荟萃, 2025, 40(6): 513-518.
[3]	李芳芳, 刘亚首, 夏磊. 外周血Hcy、D-D、NLR结合PLR对急性脑梗死溶栓治疗后复发的预测价值[J]. 临床荟萃, 2025, 40(3): 217-221.
[4]	王春杰, 谢静, 韩雪, 吴丹, 陈建华. 个体化血液透析对老年糖尿病肾病患者透析并发症的影响[J]. 临床荟萃, 2024, 39(4): 332-336.
[5]	孙帅刚, 翟亚玲, 张文惠, 田慧娟. 扁桃体切除术治疗IgA肾病的疗效评价:一项meta分析[J]. 临床荟萃, 2024, 39(3): 197-207.
[6]	王九雪, 李娜, 靳玮, 王硕, 常雅君, 王天俊. 帕金森病患者血清尿酸、同型半胱氨酸和胱抑素C水平与运动症状及认知功能的相关性[J]. 临床荟萃, 2024, 39(2): 125-129.
[7]	李佳文, 刘艳兰, 李瑶霜, 邱慧娜, 李芳, 毋帆, 林辰莹, 林静娜. 2型糖尿病患者TyG指数及其衍生指数与糖尿病肾病风险的相关性[J]. 临床荟萃, 2024, 39(10): 901-908.
[8]	杨星梦, 马晓迎, 生玉平, 刘烨, 张浩然, 徐海平, 王娜, 孙福云. 慢性肾脏病5期非透析患者同型半胱氨酸与腹主动脉钙化的相关性[J]. 临床荟萃, 2024, 39(1): 30-33.
[9]	陈婷, 刘金彦. 中药靶向PI3K/Akt/mTOR通路调节自噬在糖尿病肾脏病中的研究进展[J]. 临床荟萃, 2023, 38(6): 564-568.
[10]	李娜娜, 江珊. 血清同型半胱氨酸、胱抑素C、超敏C-反应蛋白水平对急性ST段抬高型心肌梗死患者PCI术后并发心力衰竭的预测价值[J]. 临床荟萃, 2023, 38(2): 121-125.
[11]	李会芳, 苗霞. 甲状腺激素水平对2型糖尿病肾脏病风险的预测[J]. 临床荟萃, 2023, 38(2): 137-142.
[12]	江吉, 朱小刚, 姜山, 达哇扎巴, 岑强. 世居高原高血压人群蛋白尿相关危险因素[J]. 临床荟萃, 2023, 38(12): 1086-1090.
[13]	徐阳, 薛凌. H型高血压合并2型糖尿病患者轻度认知功能障碍的影响因素[J]. 临床荟萃, 2023, 38(10): 887-892.
[14]	丁思奇, 刘时华, 张超, 钟平, 曹立. 迟发性卒中后癫痫的危险因素及其与血Hcy、hs-CRP和D-D的相关性[J]. 临床荟萃, 2023, 38(10): 893-897.
[15]	王翠, 林昊, 武萍萍, 张雅丽, 任建, 徐婷, 董国玉, 宰国田. 2型糖尿病患者高同型半胱氨酸血症与早期肾脏疾病的相关性[J]. 临床荟萃, 2023, 38(1): 42-45.